UK MHRA AI Scribe Regulation: New Guidance for Ambient Voice Technology

This episode breaks down the UK MHRA's new guidance issued on July 29, 2026, clarifying when Ambient Voice Technology (AVT), or 'AI Scribes,' are regulated as medical devices. We explain the critical distinction: products for simple transcription or note-drafting with clinician review are not devices, while those supporting diagnosis or automated actions are. We cover the implications for AI developers and NHS providers and outline practical steps for compliance and safe adoption under the UK MDR. Key Questions: - What is Ambient Voice Technology (AVT) or an 'AI Scribe'? - When is an AI Scribe considered a medical device in the UK? - What did the MHRA's new guidance on July 29, 2026, clarify? - How does this affect AI software developers targeting the NHS? - What are the compliance requirements under the UK MDR for regulated AVT products? - What due diligence should healthcare providers perform before adopting AI Scribes? - How does the role of clinician review impact the regulatory status of an AVT product? - What practical steps should manufacturers take to assess their product's classification? Sources: - https://www.gov.uk/government/news/mhra-clarifies-regulatory-status-of-ambient-voice-technologies-used-in-the-nhs How Pure Global can help: Pure Global offers end-to-end regulatory consulting for MedTech and IVD companies, helping you navigate complex requirements for Software as a Medical Device (SaMD) and AI-driven technologies. Our experts develop efficient regulatory strategies for market access in the UK and over 30 other countries, managing technical dossier compilation and submission. We act as your local representative, ensuring ongoing compliance through post-market surveillance and continuous regulatory monitoring. To access global markets faster, contact us at [email protected] or visit https://pureglobal.com. Explore our free AI regulatory tools and global device database at https://pureglobal.ai.